Galmed Pharmaceuticals (NASDAQ:GLMD) versus Its Rivals Head to Head Comparison

Galmed Pharmaceuticals (NASDAQ: GLMD) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Galmed Pharmaceuticals to similar businesses based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, earnings, risk and valuation.

Profitability

This table compares Galmed Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Galmed Pharmaceuticals -1,242.49% -167.83% -110.52%
Galmed Pharmaceuticals Competitors -5,441.68% -162.70% -35.92%

Institutional and Insider Ownership

9.9% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.4% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Galmed Pharmaceuticals has a beta of 2.47, indicating that its stock price is 147% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals’ peers have a beta of 5.84, indicating that their average stock price is 484% more volatile than the S&P 500.

Valuation & Earnings

This table compares Galmed Pharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Galmed Pharmaceuticals $470,000.00 -$16.95 million -9.97
Galmed Pharmaceuticals Competitors $290.27 million $35.99 million 60.31

Galmed Pharmaceuticals’ peers have higher revenue and earnings than Galmed Pharmaceuticals. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and target prices for Galmed Pharmaceuticals and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galmed Pharmaceuticals 0 0 4 0 3.00
Galmed Pharmaceuticals Competitors 1134 3426 11925 240 2.67

Galmed Pharmaceuticals presently has a consensus target price of $20.75, suggesting a potential upside of 87.44%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.58%. Given Galmed Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe Galmed Pharmaceuticals is more favorable than its peers.

Summary

Galmed Pharmaceuticals peers beat Galmed Pharmaceuticals on 9 of the 13 factors compared.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company’s Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply